Case Report: Exceptional Disease Progression in a 70-year-old Patient: Generalized Melanosis and Melanuria in the Course of Metastatic Melanoma - a Case Study

Overview

Journal Front Oncol

Specialty Oncology

Date 2024 Feb 13

PMID 38347840

Authors

Jacek Calik

Piotr Dziegiel

Natalia Sauer

Affiliations

Soon will be listed here.

Abstract

This case study documents an extraordinary disease progression in a 70-year-old patient diagnosed with metastatic melanoma. The patient's condition advanced to an unusual manifestation characterized by generalized melanosis and melanuria, a rare and foreboding complication of metastatic melanoma. The clinical presentation involved rapid-onset skin darkening, primarily affecting the face and torso, along with darkened urine, marking the onset of melanuria. Despite extensive diagnostic evaluations, including abdominal ultrasound, neck ultrasound, thoracic CT scans, and endoscopic examinations, the exact metastatic sites remained elusive, demonstrating the diagnostic challenges associated with this condition. Laboratory tests revealed abnormal hematological and biochemical markers, along with elevated S100 protein levels, indicating disease progression. The patient underwent a surgical skin biopsy that confirmed the diagnosis of metastatic melanoma, leading to a multidisciplinary approach to treatment. Following this, the patient-initiated chemotherapy with dacarbazine (DTIC). Regrettably, this was necessitated by the absence of reimbursement for BRAF and MEK inhibitors as well as immunotherapy, and it subsequently led to rapid disease progression and a decline in the patient's clinical condition. The patient's condition further complicated with erysipelas and increased distress, ultimately leading to their unfortunate demise. This case highlights the aggressive nature of generalized melanosis, characterized by a rapid clinical course, substantial pigmentation, and limited response to conventional chemotherapy. Importantly, the patient had a BRAF mutation, emphasizing the urgency of exploring alternative treatment strategies. Patients with a BRAF mutation are excellent candidates for BRAF and MEK inhibitor treatment, potentially allowing them to extend their lifespan if this therapy were available. The challenges encountered in diagnosing, managing, and treating this aggressive form of metastatic melanoma underline the need for early detection, tailored therapeutic approaches, and ongoing research efforts to improve patient outcomes in such cases.

References

Slominski A, Zmijewski M, Pawelek J . L-tyrosine and L-dihydroxyphenylalanine as hormone-like regulators of melanocyte functions. Pigment Cell Melanoma Res. 2011; 25(1):14-27. PMC: 3242935. DOI: 10.1111/j.1755-148X.2011.00898.x. View

Slominski R, Raman C, Chen J, Slominski A . How cancer hijacks the body's homeostasis through the neuroendocrine system. Trends Neurosci. 2023; 46(4):263-275. PMC: 10038913. DOI: 10.1016/j.tins.2023.01.003. View

Sigurdardottir V, Bolund C, Brandberg Y, Sullivan M . The impact of generalized malignant melanoma on quality of life evaluated by the EORTC questionnaire technique. Qual Life Res. 1993; 2(3):193-203. DOI: 10.1007/BF00435223. View

Greenwald H, Friedman E, Osman I . Superficial spreading and nodular melanoma are distinct biological entities: a challenge to the linear progression model. Melanoma Res. 2011; 22(1):1-8. PMC: 3253944. DOI: 10.1097/CMR.0b013e32834e6aa0. View

Tsukamoto K, Furue M, Sato Y, Takayama O, Akasu R, Ohtake N . Generalized melanosis in metastatic malignant melanoma: the possible role of DOPAquinone metabolites. Dermatology. 1999; 197(4):338-42. DOI: 10.1159/000018028. View

Fajuyigbe D, Lwin S, Diffey B, Baker R, Tobin D, Sarkany R . Melanin distribution in human epidermis affords localized protection against DNA photodamage and concurs with skin cancer incidence difference in extreme phototypes. FASEB J. 2018; 32(7):3700-3706. DOI: 10.1096/fj.201701472R. View

Gambichler T, Stucker M, Kerner K, Weiner S, Waldherr R, Altmeyer P . Acute kidney injury in a patient with melanuria, diffuse melanosis, and metastatic malignant melanoma. Am J Clin Dermatol. 2008; 9(4):267-70. DOI: 10.2165/00128071-200809040-00007. View

Middleton M, Grob J, Aaronson N, Fierlbeck G, Tilgen W, Seiter S . Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol. 2000; 18(1):158-66. DOI: 10.1200/JCO.2000.18.1.158. View

Eide J . Pathogenesis of generalized melanosis with melanuria and melanoptysis secondary to malignant melanoma. Histopathology. 1981; 5(3):285-94. DOI: 10.1111/j.1365-2559.1981.tb01787.x. View

10.

Slominski A, Paus R . Are L-tyrosine and L-dopa hormone-like bioregulators?. J Theor Biol. 1990; 143(1):123-38. DOI: 10.1016/s0022-5193(05)80292-9. View

11.

Slominski A, Moellmann G, Kuklinska E, BOMIRSKI A, Pawelek J . Positive regulation of melanin pigmentation by two key substrates of the melanogenic pathway, L-tyrosine and L-dopa. J Cell Sci. 1988; 89 ( Pt 3):287-96. DOI: 10.1242/jcs.89.3.287. View

12.

Jitian Mihulecea C, Rotaru M . Review: The Key Factors to Melanomagenesis. Life (Basel). 2023; 13(1). PMC: 9866207. DOI: 10.3390/life13010181. View

13.

Perez A, Turajlic S, Szyszko T, ODoherty M, Calonje E, Harries M . Generalized melanosis and melanuria in a patient with metastatic melanoma. Clin Exp Dermatol. 2010; 35(3):e37-9. DOI: 10.1111/j.1365-2230.2009.03545.x. View

14.

Slominski A, Kim T, Brozyna A, Janjetovic Z, Brooks D, Schwab L . The role of melanogenesis in regulation of melanoma behavior: melanogenesis leads to stimulation of HIF-1α expression and HIF-dependent attendant pathways. Arch Biochem Biophys. 2014; 563:79-93. PMC: 4221528. DOI: 10.1016/j.abb.2014.06.030. View

15.

Busam K, Wolchok J, Jungbluth A, Chapman P . Diffuse melanosis after chemotherapy-induced tumor lysis syndrome in a patient with metastatic melanoma. J Cutan Pathol. 2004; 31(3):274-80. DOI: 10.1111/j.0303-6987.2003.00154.x. View

16.

Mangana J, Felderer L, Cheng P, French L, Dummer R, Schad K . Diffuse Cutaneous Melanosis Associated with Malignant Melanoma. Ann Dermatol. 2016; 27(6):780-1. PMC: 4695441. DOI: 10.5021/ad.2015.27.6.780. View

17.

Guerry 5th D, Schuchter L . Disseminated melanoma--is there a new standard therapy?. N Engl J Med. 1992; 327(8):560-1. DOI: 10.1056/NEJM199208203270811. View

18.

Sexton M, Snyder C . Generalized melanosis in occult primary melanoma. J Am Acad Dermatol. 1989; 20(2 Pt 1):261-6. DOI: 10.1016/s0190-9622(89)70032-3. View

19.

Rzepka Z, Buszman E, Beberok A, Wrzesniok D . From tyrosine to melanin: Signaling pathways and factors regulating melanogenesis. Postepy Hig Med Dosw (Online). 2016; 70(0):695-708. DOI: 10.5604/17322693.1208033. View

20.

Bohm M, Schiller M, Nashan D, Stadler R, Luger T, Metze D . Diffuse melanosis arising from metastatic melanoma: pathogenetic function of elevated melanocyte peptide growth factors. J Am Acad Dermatol. 2001; 44(5):747-54. DOI: 10.1067/mjd.2001.112349. View